Vicore Pharma Holding AB has entered into an agreement to acquire INIM Pharma AB, a Swedish biopharmaceutical company developing a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. Payment for the acquisition is effectuated through an issue in kind, corresponding to a dilution of 35.8 percent. The Board of Directors of Vicore has decided to propose a rights issue of approximately SEK 80 million.
